港股異動 | 澳優(1717.HK)續升5%創近3個月新高 績後獲投行唱好
格隆匯5月13日丨澳優(1717.HK)再度拉昇漲4.73%,績後兩日連升超18%。在大市下跌中,表現尤為亮眼。現報12.84港元創近3個月新高價,總市值219億港元。澳優Q1實現歸母淨利潤3.3億元,同比增22.9%。國盛證券點評稱,在20Q1收入基數較高,2021嬰配粉市場整體競爭加劇的情況下,公司取得雙位數增長,表現超市場預期。預測公司牛奶粉2021年營收將維持高雙位數增長,維持其“買入”評級,目標價15.4港元。花旗則微升澳優目標價1%至13.82港元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.